Financial & Business News

NEW YORK, Dec. 22, 2024 (GLOBE NEWSWIRE) -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Unisys Corporation (NYSE: UIS) resulting from allegations that Unisys may have issued materially misleading business information to the investing public.

I initially doubted Roundhill's derivative ETFs, but now endorse XDTE for its impressive total return and lower volatility compared to benchmarks. XDTE's strategy involves buying long-dated ITM calls and selling ATM calls daily, generating significant distributable income and outperforming the S&P 500. Despite some inconsistencies and recent underperformance, XDTE offers a unique, lower-volatility income source suitable for aggressive and conservative income investors.

NEW YORK, Dec. 22, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 18, 2025.

Nu Holdings, founded in 2013, now serves 110 million customers across Brazil, Mexico, and Colombia, capturing 56% of Brazil's adult population. Despite a 24% YTD stock increase, NU remains 29% below its October highs, presenting a compelling investment opportunity given its strong Q3 2024 results. Nubank showcases some of the best unit economics in public markets through compounding cross-selling opportunities to clients.

NEW YORK, NY / ACCESSWIRE / December 22, 2024 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=118081&wire=1 or contact Joseph E. Levi, Esq.

Pfizer's stock has underperformed, but management's focus on R&D and cost efficiencies should boost margins and free cash flow, supporting a Buy rating. Despite political headwinds, PFE's valuation at 9x 2025 EPS and a 6.5% dividend yield make it attractive for long-term investors. Management's 2025 guidance indicates flat sales but improved profitability, with gross margins expected to reach the upper 70s, enhancing shareholder value and supporting its strong dividend payouts.

NEW YORK, NY / ACCESSWIRE / December 22, 2024 / If you suffered a loss on your Aehr Test Systems, Inc. (NASDAQ:AEHR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/aehr-lawsuit-submission-form?prid=118080&wire=1 or contact Joseph E. Levi, Esq.

Oil prices rose in early Asian trading amid low inventories.

YieldMax NVDA Option Income Strategy ETF offers high distribution yields by selling short-dated, slightly out-of-the-money calls on NVIDIA, but its attractiveness depends on NVIDIA's volatility. The distribution rate has dropped from 106.86% to 67.78%, reflecting changes in call premiums due to NVIDIA's volatility and market demand. Selling covered calls on NVDA can be challenging, and while it offers income, it limits upside potential and doesn't significantly reduce downside risk.

NEW YORK, NY / ACCESSWIRE / December 22, 2024 / If you suffered a loss on your Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/evolv-technologies-holdings-inc-lawsuit-submission-form-2?prid=118079&wire=1 or contact Joseph E. Levi, Esq.